Light chain amyloidosis 2012: a new era. (Q38072108)

28 August 2017

1 reference

title

Light chain amyloidosis 2012: a new era. (English)

1 reference

28 August 2017

2

1 reference

28 August 2017

Moshe E Gatt

1

1 reference

PubMed ID

23294331

28 August 2017

language of work or name

English

0 references

publication date

7 January 2013

1 reference

British Journal of Haematology

28 August 2017

1 reference

28 August 2017

160

1 reference

28 August 2017

5

1 reference

28 August 2017

582-598

1 reference

High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma.

28 August 2017

1 reference

Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias

21 January 2018

1 reference

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

21 January 2018

1 reference

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

21 January 2018

1 reference

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

21 January 2018

1 reference

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

21 January 2018

1 reference

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins.

21 January 2018

1 reference

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

21 January 2018

1 reference

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure

21 January 2018

1 reference

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

21 January 2018

1 reference

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

21 January 2018

1 reference

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

21 January 2018

1 reference

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

21 January 2018

1 reference

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

21 January 2018

1 reference

EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers

21 January 2018

1 reference

Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation

21 January 2018

1 reference

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.

21 January 2018

1 reference

Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.

21 January 2018

1 reference

IgM amyloidosis: clinical features in therapeutic outcomes

21 January 2018

1 reference

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis

21 January 2018

1 reference

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

21 January 2018

1 reference

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

21 January 2018

1 reference

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report

21 January 2018

1 reference

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

21 January 2018

1 reference

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

21 January 2018

1 reference

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later

21 January 2018

1 reference

Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis

21 January 2018

1 reference

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

21 January 2018

1 reference

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis

21 January 2018

1 reference

Proteomic typing of amyloid deposits in systemic amyloidoses.

21 January 2018

1 reference

Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

21 January 2018

1 reference

IMWG consensus on maintenance therapy in multiple myeloma

21 January 2018

1 reference

Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma

21 January 2018

1 reference

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement

21 January 2018

1 reference

Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure

21 January 2018

1 reference

Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis.

21 January 2018

1 reference

Molecular mechanisms of amyloidosis

21 January 2018

1 reference

Dangerous small B-cell clones.

21 January 2018

1 reference

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies

21 January 2018

1 reference

Amyloidosis: pathogenesis and new therapeutic options.

21 January 2018

1 reference

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

21 January 2018

1 reference

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

21 January 2018

1 reference

Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study

21 January 2018

1 reference

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

Clinical aspects of systemic amyloid diseases.

21 January 2018

1 reference

Transplantation vs. conventional-dose therapy for amyloidosis

21 January 2018

1 reference

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

21 January 2018

1 reference

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

21 January 2018

1 reference

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

21 January 2018

1 reference

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

21 January 2018

1 reference

Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.

21 January 2018

1 reference

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

21 January 2018

1 reference

21 January 2018

1 reference

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

Amyloid in bone marrow smears of patients affected by multiple myeloma

21 January 2018

1 reference

Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules

21 January 2018

1 reference

Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

21 January 2018

1 reference

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation

21 January 2018

1 reference

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

21 January 2018

1 reference

Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients.

21 January 2018

1 reference

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

21 January 2018

1 reference

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

21 January 2018

1 reference

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

21 January 2018

1 reference

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

Kidney dysfunction during lenalidomide treatment for AL amyloidosis.

21 January 2018

1 reference

Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis

21 January 2018

1 reference

Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.

21 January 2018

1 reference

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

Therapeutic advances demand accurate typing of amyloid deposits

21 January 2018

1 reference

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

21 January 2018

1 reference

Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits

21 January 2018

1 reference

CyBorD: stellar response rates in AL amyloidosis

21 January 2018

1 reference

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

21 January 2018

1 reference

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

21 January 2018

1 reference

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study

21 January 2018

1 reference

Natural polyphenols as modulators of TTR amyloidogenesis:in vitroandin vivoevidences towards therapy

21 January 2018

1 reference

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

21 January 2018

1 reference

Solid Organ Transplantation in AL Amyloidosis

21 January 2018

1 reference

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

21 January 2018

1 reference

AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12191

1 reference

28 August 2017

1 reference

PubMed ID

23294331